PFS Investments’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

PFS Investments’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,414	Closed	-$371K	–	543
2023 Q1	$371K	Sell	3,414 -15,907	-82%	-$1.76M	0.01%	403
2022 Q4	$2.2M	Sell	19,321 -424	-2%	-$35.2K	0.04%	276
2022 Q3	$1.22K	Sell	19,745 -55,787	-74%	-$3.9M	0.02%	319
2022 Q2	$6.02M	Buy	75,532 +5,712	+8%	+$541K	0.12%	165
2022 Q1	$7.35M	Buy	69,820 +9,471	+16%	+$923K	0.14%	144
2021 Q4	$6.5M	Buy	60,349 +5,130	+9%	+$560K	0.13%	162
2021 Q3	$5.97M	Buy	55,219 +3,984	+8%	+$414K	0.12%	153
2021 Q2	$4.88M	Buy	51,235 +2,519	+5%	+$232K	0.11%	165
2021 Q1	$4.48M	Buy	48,716 +26,044	+115%	+$2.2M	0.11%	160
2020 Q4	$1.78M	Buy	22,672 +4,468	+25%	+$332K	0.05%	231
2020 Q3	$1.41M	Buy	+18,204	New	+$1.25M	0.05%	220

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PFS Investments's HZNP Position: Q2 2023 in Review

PFS Investments sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 3,414 shares — an estimated $371K sold.

PFS Investments first reported a position in HZNP in Q3 2020 and held it in 11 quarters. The position peaked at $7.35M in Q1 2022. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

PFS Investments reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
PFS Investments sold 3,414 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $371K.
PFS Investments first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 11 quarters.
PFS Investments's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $7.35M in Q1 2022.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on PFS Investments's 13F filing for Q2 2023, filed 14 Aug 2023.